Galcanezumab (CALCA/CGRP1/CALCB/CGRP2) - Research Grade Biosimilar
Product Specifications
Background
LY2951742/galcanezumab is a fully humanized monoclonal antibody against human calcitonin gene-related peptide (CGRP) that is developed by ELi Lilly and Company.This therapy is given as a single subcutaneous injection twice a month and ongoing clinical trials for the agent are for episodic and chronic migraine as well as cluster headaches.
Immunogen
Humanized / CALCA/CGRP1/CALCB/CGRP2 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Neuroscience
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-773
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Other Product Names
LY-2951742, galcanezumab-gnlm
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rat Monoclonal GM-CSF Antibody (SPM469) [Alexa Fluor 532]](https://cdn.genprice.uk/genprice/genprice4.png)
